The HM3 LVAS is intended to provide hemodynamic support in patients with advanced, refractory left ventricular heart failure; either for short term support, such as a bridge to cardiac transplantation (BTT) or myocardial recovery, or as long term support, such as destination therapy (DT). The HM3 is intended for use inside or outside the hospital.
Continued evaluation of safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure.
Location: SIMR (Sacramento/Valley Area)
Please contact email@example.com about Study MOMENTUM 3
View study details on ClinicalTrials.gov
October 17, 2016
Investigator(s): Andrew Hudnut, MD